John Hussman's TGTX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 126.0K shares of TG Therapeutics, Inc. (TGTX) worth $4.55 M, representing 0.99% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 9 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 73.5K shares. Largest reduction occurred in Q4 2024, reducing 63.0K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2023 | +52,500 | New Buy | 52,500 | $8.36 |
| Q4 2023 | -52,500 | Sold Out | 52,500 | $0.00 |
| Q3 2024 | +105,000 | New Buy | 105,000 | $23.39 |
| Q4 2024 | -63,000 | Reduce 60.00% | 42,000 | $30.10 |
| Q1 2025 | +10,500 | Add 25.00% | 52,500 | $39.43 |
| Q2 2025 | +73,500 | Add 140.00% | 126,000 | $35.99 |
John Hussman's TG Therapeutics Investment FAQs
John Hussman first purchased TG Therapeutics, Inc. (TGTX) in Q3 2023, acquiring 52,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held TG Therapeutics, Inc. (TGTX) for 9 quarters since Q3 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to TG Therapeutics, Inc. (TGTX) was in Q3 2024, adding 105,000 shares worth $2.46 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 126,000 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $4.55 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.99% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in TG Therapeutics, Inc. (TGTX) was 126,000 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.